🇺🇸 FDA
Pipeline program

Dipyridamole 50mg tid

2025-451-02

Phase 3 small_molecule active

Quick answer

Dipyridamole 50mg tid for Restless Leg Syndrome Due to Uraemia is a Phase 3 program (small_molecule) at First Tracks Biotherapeutics with 1 ClinicalTrials.gov record(s).

Program details

Company
First Tracks Biotherapeutics
Indication
Restless Leg Syndrome Due to Uraemia
Phase
Phase 3
Modality
small_molecule
Status
active

Clinical trials